mdm2-p53 Interaction: Lack of Correlation with the Response to 5-Fluorouracil in Advanced Colorectal Cancer

Publisher： Karger

E-ISSN： 1423-0232|62|3|278-285

ISSN： 0030-2414

Source： Oncology, Vol.62, Iss.3, 2002-06, pp. : 278-285

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Targeted nutlin-3a loaded nanoparticles inhibiting p53––MDM2 interaction: novel strategy for breast cancer therapy

By Das Manasi   Dilnawaz Fahima   Sahoo Sanjeeb K  

Nanomedicine, Vol. 6, Iss. 3, 2011-04 ,pp. : 489-507

Future Medicine

Access to resources Recommend Favorite

Clinical Significance of mdm2 and p53 Expression in Bladder Cancer

By  

Oncology, Vol. 56, Iss. 3, 1999-04 ,pp. : 239-247

Karger

Access to resources Recommend Favorite

Combined Irinotecan, Oxaliplatin and 5-Fluorouracil in Patients with Advanced Colorectal Cancer

By  

Oncology, Vol. 63, Iss. 3, 2002-10 ,pp. : 254-265

Karger

Access to resources Recommend Favorite

Oxaliplatin in Combination with Infusional 5-Fluorouracil and Leucovorin Every 2 Weeks as First-Line Treatment in Patients with Advanced Colorectal Cancer: A Phase II Study

By  

Oncology, Vol. 61, Iss. 1, 2001-07 ,pp. : 36-41

Karger

Access to resources Recommend Favorite

The Role of 5-Fluorouracil (5-FU) Reintroduction with Irinotecan or Oxaliplatin in Truly 5-FU-Refractory Advanced Colorectal Cancer Patients

By  

Oncology, Vol. 68, Iss. 2-3, 2005-07 ,pp. : 212-216

Karger

Access to resources Recommend Favorite